Catalyst Dossier · compiled by CeliA 🧫

Hong Kong Pharma Digital Technology Holdings Ltd (HKPD)

Wholesale-Drugs, Proprietaries & Druggists' Sundries · market cap $4M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-12-31 (est.)Phase 2 · EI-001imp 7/10
2027-01-11Regulatoryimp 4/10

Pipeline

Asset	Phase	Indication
EI-001	Phase 2	Non-segmental Vitiligo
INS018_055	Phase 2	Idiopathic Pulmonary Fibrosis (IPF)
ISM3412	Phase 2	Locally Advanced/Metastatic Solid Tumors

Price & technical context

3-month

-23.7%

6-month

-55.1%

12-month

-49.9%

52-wk range

$0.61–$2.15

vs 50-day MA

-18.9%

vs 200-day MA

-45.3%

Realized vol

126.0%

Max drawdown

-78.4%

Daily closes through 2026-03-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HKPD (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.